Conservest Capital Advisors Inc. Decreases Stock Holdings in VanEck Biotech ETF (NASDAQ:BBH)

Conservest Capital Advisors Inc. trimmed its stake in shares of VanEck Biotech ETF (NASDAQ:BBH) by 3.0% in the 4th quarter, Holdings Channel reports. The firm owned 17,683 shares of the company’s stock after selling 548 shares during the period. Conservest Capital Advisors Inc.’s holdings in VanEck Biotech ETF were worth $2,776,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Truvestments Capital LLC purchased a new position in shares of VanEck Biotech ETF during the third quarter valued at approximately $44,000. FSA Wealth Management LLC purchased a new position in shares of VanEck Biotech ETF during the third quarter valued at approximately $54,000. Coastline Trust Co purchased a new position in shares of VanEck Biotech ETF during the third quarter valued at approximately $59,000. Wilmington Savings Fund Society FSB purchased a new position in shares of VanEck Biotech ETF during the third quarter valued at approximately $166,000. Finally, Commonwealth Retirement Investments LLC purchased a new position in shares of VanEck Biotech ETF during the fourth quarter valued at approximately $215,000. 32.05% of the stock is owned by hedge funds and other institutional investors.

VanEck Biotech ETF Price Performance

BBH opened at $164.58 on Friday. VanEck Biotech ETF has a twelve month low of $151.35 and a twelve month high of $183.64. The firm has a 50 day moving average price of $161.48 and a 200-day moving average price of $169.13.

VanEck Biotech ETF Dividend Announcement

The firm also recently announced a dividend, which was paid on Tuesday, December 24th. Shareholders of record on Monday, December 23rd were issued a dividend of $1.2517 per share. The ex-dividend date was Monday, December 23rd.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.